Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2

K. Müller-Decker, Annette Kopp-Schneider, F. Marks, K. Seibert, G. Fürstenberger

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The growth factor- and phorbol ester-inducible prostaglandin H synthase (PGHS)-2 has been found to be constitutively overexpressed in epidermal tumors generated by the initiation-promotion protocol in murine skin, whereas the expression of PGHS-1 does not change under these conditions. In this paper we report the intra-tumor distribution of the aberrantly expressed PGHS-2 and the cancer chemopreventive activity of a specific PGHS-2 inhibitor. By immunohistochemical methods using isoenzyme-specific antibodies, we found that the PGHS-1 protein was expressed in keratinocytes and Langerhans cells dispersed throughout the epithelial part of papillomas and squamous cell carcinomas and in inflammatory infiltrates occasionally seen in these tumors. A uniform pattern of PGHS-2 expression was observed in the basal keratinocytes of papillomas and in the follicular keratinocytes of carcinomas. In addition, Langerhans cells as well as tumor-associated inflammatory infiltrates exhibited PGHS-2-specific immunoreactivity. PGHS-2- catalyzed prostaglandin synthesis stimulated by the phorbol ester 12-O- tetradecanoylphorbol-13 acetate (TPA) in mouse epidermis in vivo was dose- dependently suppressed by topical administration of SC-58125, a specific PGHS-2 inhibitor. TPA-induced edema formation, epidermal DNA synthesis, and mitotic activity were not impaired by SC-58125 applied at a dose that inhibited TPA-induced prostaglandin E2 synthesis. However, the repetitive epicutaneous administration of SC-58125 substantially and significantly suppressed papilloma development. Malignant progression of papillomas was slightly retarded by the drug. These results indicate that aberrant expression of PGHS-2 in epidermal tumors may be a relevant target for prevention of epidermal cancer development in experimental animals and that the PGHS-2-specific inhibitor SC-58125, which is a potent inhibitor of tumor promotion in mouse skin, may be important for cancer chemoprevention in humans as well.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalMolecular Carcinogenesis
Volume23
Issue number1
DOIs
StatePublished - Sep 1998

Fingerprint

Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Isoenzymes
Skin
Papilloma
Neoplasms
Tetradecanoylphorbol Acetate
Keratinocytes
Cyclooxygenase 1
Langerhans Cells
Phorbol Esters
Topical Administration
Chemoprevention
Dinoprostone
Epidermis
Prostaglandins
Squamous Cell Carcinoma
Edema
Intercellular Signaling Peptides and Proteins
Carcinoma

Keywords

  • Chemoprevention
  • Cyclooxygenase
  • Immunohistochemistry
  • Keratinocyte
  • Langerhans cell
  • Multistage skin carcinogenesis
  • Nonsteroidal anti-inflammatory drug
  • Prostaglandin H synthase
  • SC-58125

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology

Cite this

Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors : Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. / Müller-Decker, K.; Kopp-Schneider, Annette; Marks, F.; Seibert, K.; Fürstenberger, G.

In: Molecular Carcinogenesis, Vol. 23, No. 1, 09.1998, p. 36-44.

Research output: Contribution to journalArticle

@article{002798035dda4b53ac33664fc445b1e4,
title = "Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2",
abstract = "The growth factor- and phorbol ester-inducible prostaglandin H synthase (PGHS)-2 has been found to be constitutively overexpressed in epidermal tumors generated by the initiation-promotion protocol in murine skin, whereas the expression of PGHS-1 does not change under these conditions. In this paper we report the intra-tumor distribution of the aberrantly expressed PGHS-2 and the cancer chemopreventive activity of a specific PGHS-2 inhibitor. By immunohistochemical methods using isoenzyme-specific antibodies, we found that the PGHS-1 protein was expressed in keratinocytes and Langerhans cells dispersed throughout the epithelial part of papillomas and squamous cell carcinomas and in inflammatory infiltrates occasionally seen in these tumors. A uniform pattern of PGHS-2 expression was observed in the basal keratinocytes of papillomas and in the follicular keratinocytes of carcinomas. In addition, Langerhans cells as well as tumor-associated inflammatory infiltrates exhibited PGHS-2-specific immunoreactivity. PGHS-2- catalyzed prostaglandin synthesis stimulated by the phorbol ester 12-O- tetradecanoylphorbol-13 acetate (TPA) in mouse epidermis in vivo was dose- dependently suppressed by topical administration of SC-58125, a specific PGHS-2 inhibitor. TPA-induced edema formation, epidermal DNA synthesis, and mitotic activity were not impaired by SC-58125 applied at a dose that inhibited TPA-induced prostaglandin E2 synthesis. However, the repetitive epicutaneous administration of SC-58125 substantially and significantly suppressed papilloma development. Malignant progression of papillomas was slightly retarded by the drug. These results indicate that aberrant expression of PGHS-2 in epidermal tumors may be a relevant target for prevention of epidermal cancer development in experimental animals and that the PGHS-2-specific inhibitor SC-58125, which is a potent inhibitor of tumor promotion in mouse skin, may be important for cancer chemoprevention in humans as well.",
keywords = "Chemoprevention, Cyclooxygenase, Immunohistochemistry, Keratinocyte, Langerhans cell, Multistage skin carcinogenesis, Nonsteroidal anti-inflammatory drug, Prostaglandin H synthase, SC-58125",
author = "K. M{\"u}ller-Decker and Annette Kopp-Schneider and F. Marks and K. Seibert and G. F{\"u}rstenberger",
year = "1998",
month = "9",
doi = "10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F",
language = "English (US)",
volume = "23",
pages = "36--44",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors

T2 - Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2

AU - Müller-Decker, K.

AU - Kopp-Schneider, Annette

AU - Marks, F.

AU - Seibert, K.

AU - Fürstenberger, G.

PY - 1998/9

Y1 - 1998/9

N2 - The growth factor- and phorbol ester-inducible prostaglandin H synthase (PGHS)-2 has been found to be constitutively overexpressed in epidermal tumors generated by the initiation-promotion protocol in murine skin, whereas the expression of PGHS-1 does not change under these conditions. In this paper we report the intra-tumor distribution of the aberrantly expressed PGHS-2 and the cancer chemopreventive activity of a specific PGHS-2 inhibitor. By immunohistochemical methods using isoenzyme-specific antibodies, we found that the PGHS-1 protein was expressed in keratinocytes and Langerhans cells dispersed throughout the epithelial part of papillomas and squamous cell carcinomas and in inflammatory infiltrates occasionally seen in these tumors. A uniform pattern of PGHS-2 expression was observed in the basal keratinocytes of papillomas and in the follicular keratinocytes of carcinomas. In addition, Langerhans cells as well as tumor-associated inflammatory infiltrates exhibited PGHS-2-specific immunoreactivity. PGHS-2- catalyzed prostaglandin synthesis stimulated by the phorbol ester 12-O- tetradecanoylphorbol-13 acetate (TPA) in mouse epidermis in vivo was dose- dependently suppressed by topical administration of SC-58125, a specific PGHS-2 inhibitor. TPA-induced edema formation, epidermal DNA synthesis, and mitotic activity were not impaired by SC-58125 applied at a dose that inhibited TPA-induced prostaglandin E2 synthesis. However, the repetitive epicutaneous administration of SC-58125 substantially and significantly suppressed papilloma development. Malignant progression of papillomas was slightly retarded by the drug. These results indicate that aberrant expression of PGHS-2 in epidermal tumors may be a relevant target for prevention of epidermal cancer development in experimental animals and that the PGHS-2-specific inhibitor SC-58125, which is a potent inhibitor of tumor promotion in mouse skin, may be important for cancer chemoprevention in humans as well.

AB - The growth factor- and phorbol ester-inducible prostaglandin H synthase (PGHS)-2 has been found to be constitutively overexpressed in epidermal tumors generated by the initiation-promotion protocol in murine skin, whereas the expression of PGHS-1 does not change under these conditions. In this paper we report the intra-tumor distribution of the aberrantly expressed PGHS-2 and the cancer chemopreventive activity of a specific PGHS-2 inhibitor. By immunohistochemical methods using isoenzyme-specific antibodies, we found that the PGHS-1 protein was expressed in keratinocytes and Langerhans cells dispersed throughout the epithelial part of papillomas and squamous cell carcinomas and in inflammatory infiltrates occasionally seen in these tumors. A uniform pattern of PGHS-2 expression was observed in the basal keratinocytes of papillomas and in the follicular keratinocytes of carcinomas. In addition, Langerhans cells as well as tumor-associated inflammatory infiltrates exhibited PGHS-2-specific immunoreactivity. PGHS-2- catalyzed prostaglandin synthesis stimulated by the phorbol ester 12-O- tetradecanoylphorbol-13 acetate (TPA) in mouse epidermis in vivo was dose- dependently suppressed by topical administration of SC-58125, a specific PGHS-2 inhibitor. TPA-induced edema formation, epidermal DNA synthesis, and mitotic activity were not impaired by SC-58125 applied at a dose that inhibited TPA-induced prostaglandin E2 synthesis. However, the repetitive epicutaneous administration of SC-58125 substantially and significantly suppressed papilloma development. Malignant progression of papillomas was slightly retarded by the drug. These results indicate that aberrant expression of PGHS-2 in epidermal tumors may be a relevant target for prevention of epidermal cancer development in experimental animals and that the PGHS-2-specific inhibitor SC-58125, which is a potent inhibitor of tumor promotion in mouse skin, may be important for cancer chemoprevention in humans as well.

KW - Chemoprevention

KW - Cyclooxygenase

KW - Immunohistochemistry

KW - Keratinocyte

KW - Langerhans cell

KW - Multistage skin carcinogenesis

KW - Nonsteroidal anti-inflammatory drug

KW - Prostaglandin H synthase

KW - SC-58125

UR - http://www.scopus.com/inward/record.url?scp=0031658940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031658940&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F

DO - 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F

M3 - Article

C2 - 9766436

AN - SCOPUS:0031658940

VL - 23

SP - 36

EP - 44

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 1

ER -